On this episode of Stock Movers:
- Novo Nordisk pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and Ozempic, underscoring the urgency facing its new CEO.
- Orsted has confirmed its full-year profit guidance, seeking to reassure investors of its financial stability after a weak third quarter..
- M&S expects profit in the second half to rebound to at least last year’s level as the British retailer tries to move on from a costly cyberattack.

On this episode of Stock Movers: - Novo Nordisk pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and Ozempic, underscoring the urgency facing its new CEO. - Orsted has confirmed its full-year profit guidance, seeking to reassure investors of its financial stability after a weak third quarter.. - M&amp;S expects profit in the second half to rebound to at least last year&rsquo;s level as the British retailer tries to move on from a costly cyberattack.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Novo Up, Orsted Gains, M&S Dips

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/b0cfcc59-740d-4771-9a86-b38c00aaf6da/transcript

On this episode of Stock Movers:
- Novo Nordisk (NVO) shares rallied in trading today following the drugmaker getting US approval to sell a pill version of its blockbuster obesity shot Wegovy. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term. The pill is crucial for Novo’s strategy to take on Eli Lilly, which has said its own oral obesity drug could be approved by March. That would give Novo a head start of just a few months. 
- ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. The Santa Clara, California-based enterprise tech company will pay in cash for San Francisco-based Armis, according to a statement Tuesday that confirmed an earlier Bloomberg News report. ServiceNow, which provides software that helps companies organize and automate their personnel and information technology operations, has become a dominant platform for enterprise workflow. In March, ServiceNow struck an agreement to buy the artificial intelligence firm Moveworks Inc. for $2.85 billion as part of its push into AI tools that can complete tasks without human supervision. Shares of the startup fell during trading on Tuesday.
- Sable (SOC) shares rose as much as 30% after the company said that the US Department of Transportation, Pipeline and Hazardous Materials Safety Administration approved the firm’s Las Flores pipeline restart plan.

On this episode of Stock Movers: - Novo Nordisk (NVO) shares rallied in trading today following the drugmaker getting US approval to sell a pill version of its blockbuster obesity shot Wegovy. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term. The pill is crucial for Novo&rsquo;s strategy to take on Eli Lilly, which has said its own oral obesity drug could be approved by March. That would give Novo a head start of just a few months. - ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. The Santa Clara, California-based enterprise tech company will pay in cash for San Francisco-based Armis, according to a statement Tuesday that confirmed an earlier Bloomberg News report. ServiceNow, which provides software that helps companies organize and automate their personnel and information technology operations, has become a dominant platform for enterprise workflow. In March, ServiceNow struck an agreement to buy the artificial intelligence firm Moveworks Inc. for $2.85 billion as part of its push into AI tools that can complete tasks without human supervision. Shares of the startup fell during trading on Tuesday. - Sable (SOC) shares rose as much as 30% after the company said that the US Department of Transportation, Pipeline and Hazardous Materials Safety Administration approved the firm&rsquo;s Las Flores pipeline restart plan.

Novo Nordisk Rallies, ServiceNow Dips, Sable Rises

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/8e2b4a94-214c-4021-8e16-b3bc016cf117/transcript

On this episode of Stock Movers:
- Novo Nordisk (NVO) won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly. The shares soared by as much as 11% in Copenhagen, the biggest intraday gain since August. Novo has fallen by almost half this year amid concern about the Danish drugmaker’s ability to compete in the obesity market it pioneered. Shares continued to rally in New York trading on Tuesday.
- Johnson & Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who blamed the company’s talc-based baby powder for causing her asbestos-linked cancer, the largest such verdict for an individual in 15 years of litigation. The verdict comes as J&J has been pummeled by a recent spate of baby powder verdicts after it failed this year to use bankruptcy court to force a settlement of more than 70,000 lawsuits accusing the company of hiding the product’s cancer risks. Shares of the company fell in trading on Tuesday.
- ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. Shares in ServiceNow fell about 1.3% in early trading before markets opened in New York. They closed up around 0.9% on Monday, giving the company a market valuation of about $163 billion.

On this episode of Stock Movers: - Novo Nordisk (NVO) won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly. The shares soared by as much as 11% in Copenhagen, the biggest intraday gain since August. Novo has fallen by almost half this year amid concern about the Danish drugmaker&rsquo;s ability to compete in the obesity market it pioneered. Shares continued to rally in New York trading on Tuesday. - Johnson &amp; Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who blamed the company&rsquo;s talc-based baby powder for causing her asbestos-linked cancer, the largest such verdict for an individual in 15 years of litigation. The verdict comes as J&amp;J has been pummeled by a recent spate of baby powder verdicts after it failed this year to use bankruptcy court to force a settlement of more than 70,000 lawsuits accusing the company of hiding the product&rsquo;s cancer risks. Shares of the company fell in trading on Tuesday. - ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. Shares in ServiceNow fell about 1.3% in early trading before markets opened in New York. They closed up around 0.9% on Monday, giving the company a market valuation of about $163 billion.

Novo Nordisk Rallies, Johnson & Johnson Slides, ServiceNow Falls

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/13b7eead-2540-41ee-b2c9-b3bc0150918f/transcript

On this episode of Stock Movers:
- Novo Nordisk (NOVOB) won approval to sell a pill version of its obesity shot Wegovy in the US, to help people lose weight or maintain previous weight loss over the long term. The company will start selling the pill in the US in early January, and it is approved based on the results of the Oasis 4 trial, which found people taking the pill lost about 13.6% of their body weight over 64 weeks.
- Johnson & Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who blamed the company's talc-based baby powder for causing her asbestos-linked cancer.
- ServiceNow Inc. has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. Shares have fallen over 4% on the news.

On this episode of Stock Movers: - Novo Nordisk (NOVOB) won approval to sell a pill version of its obesity shot Wegovy in the US, to help people lose weight or maintain previous weight loss over the long term. The company will start selling the pill in the US in early January, and it is approved based on the results of the Oasis 4 trial, which found people taking the pill lost about 13.6% of their body weight over 64 weeks. - Johnson &amp; Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who blamed the company's talc-based baby powder for causing her asbestos-linked cancer. - ServiceNow Inc. has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. Shares have fallen over 4% on the news.

Novo Nordisk Soars, Johnson & Johnson Drops, ServiceNow Falls

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/8f07f33f-8d50-4691-9d7e-b3bc010aca7a/transcript

Novo Up, Orsted Gains, M&S Dips

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips